|
Central neuroblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
PAC1 receptor splice variants missing a 21 amino acid sequence in the amino terminal domain were found to be the major receptor variants in the neuroblastoma cell lines and also were highly expressed in embryonic brain compared to adult brain.
|
16226889 |
2006 |
|
Central neuroblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Calmodulin interacts with PAC1 and VPAC2 receptors and regulates PACAP-induced FOS expression in human neuroblastoma cells.
|
19269029 |
2009 |
|
Central neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results provide evidence that the neurotrophic effects of PACAP-38 on human SH-SY5Y neuroblastoma cells are mediated by the PAC(1) receptor through a cAMP-dependent but PKA-independent mechanism, and furthermore suggest that this involves Epac-dependent activation of ERK as well as activation of the p38 MAP kinase signaling pathway.
|
17995938 |
2008 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using flow cytometry, the power-transformed mean percentage of PAC-1-positive platelets, [PAC-1](1/3), was significantly higher in healthy subjects with the C/C genotype than in healthy subjects with the A/A genotype (p ≤ 0.05), although there was no significant difference in patients with CI between these two genotypes.
|
23628440 |
2013 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, PAC-1 was probably known to be associated with Burkitt Lymphoma (Odds Ratio [OR] 6.67, Relative Risk [RR] 3.13, 95% CI 1.06-9.21; p = 0.02).
|
31326577 |
2019 |
|
Childhood Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time polymerase chain reaction (PCR) was used to examine the effects of haloperidol, olanzapine and amisulpride on the expression of genes coding PAC1/VPAC type receptors in the T98G glioblastoma cell line, as an example of an in vitro model of glial cells.
|
27900577 |
2017 |
|
Childhood Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Synergistic activity of PAC-1/TMZ in rodent models and the demonstration of feasibility of the combined regime in canine patients suggest potential for PAC-1 in the treatment of glioblastoma.
|
29113289 |
2017 |
|
Childhood Neuroblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Calmodulin interacts with PAC1 and VPAC2 receptors and regulates PACAP-induced FOS expression in human neuroblastoma cells.
|
19269029 |
2009 |
|
Childhood Neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results provide evidence that the neurotrophic effects of PACAP-38 on human SH-SY5Y neuroblastoma cells are mediated by the PAC(1) receptor through a cAMP-dependent but PKA-independent mechanism, and furthermore suggest that this involves Epac-dependent activation of ERK as well as activation of the p38 MAP kinase signaling pathway.
|
17995938 |
2008 |
|
Childhood Neuroblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
PAC1 receptor splice variants missing a 21 amino acid sequence in the amino terminal domain were found to be the major receptor variants in the neuroblastoma cell lines and also were highly expressed in embryonic brain compared to adult brain.
|
16226889 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
B-PAC-1 in combination with an inhibitor of apoptosis protein antagonist (Smac066) synergistically induced apoptosis in CLL samples.
|
25538042 |
2015 |
|
Chronic myeloproliferative disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Surprisingly, we found a very low PAC-1 binding capacity in MPN patients; however, the expression of PAC-1 was almost completely recovered with aspirin intake.
|
31792942 |
2019 |
|
Chronic pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In particular, the development of biased antagonists to PAC1 receptor-mediated endosomal signaling may offer therapeutic options for chronic pain and stress-related disorders..
|
27661062 |
2017 |
|
Chronic pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Previously, we found that intrathecal injection of PACAP or maxadilan, a selective PACAP type I (PAC1) receptor agonist, induced transient aversive responses followed by a long-lasting mechanical allodynia in mice, suggesting that PACAP-PAC1 receptor systems are involved in chronic pain and that selective PAC1 antagonists may become a new class of analgesics.
|
29363578 |
2018 |
|
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, these results suggest that PACAP, acting through stimulation of PAC1 receptor, may have a therapeutic potential to counteract cognitive deficits induced in HD.
|
29526016 |
2018 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the current study, we contrast the effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on the HCT8 colon cancer cell lines to the HCT116 and FET cell lines wherein PAC1 is expressed as the SV1 or HIP splice variant and is coupled to the activation only of cAMP but not of intracellular Ca2+.
|
14742913 |
2004 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
These data indicate that human colon tumor cells express PAC1 and are differentially coupled to intracellular signal transduction molecules.
|
14742913 |
2004 |
|
Congenital Hydrocephalus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Two important players are the subcommissural organ/Reissner's fiber (SCO/RF) complex and the ventricular ependymal (vel) cells that together facilitate the flow of the CSF through the narrow canals of the ventricular system.In this issue of the JCI, Lang et al. demonstrate that overexpression of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor gene results in abnormal development of the SCO and vel cells, leading to congenital hydrocephalus (see the related article beginning on page 1924).
|
16823482 |
2006 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAC1 KO demonstrate similar attributes to PACAP-null mice, but with the addition of increased pulmonary artery pressure, consequently leading to heart failure and death.
|
28392470 |
2017 |
|
Crohn Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Colon-only CD (n = 228) was compared with healthy controls: three of six UC SNPs (in MST1, HLA-DRA, and IL-23R) and 11 of 34 CD SNPs: in IRGM, NOD2 (rs2066845), CCNY, MST1, IL23R, PTPN22, C11orf30, ZNF365, PTPN2, PSMG1, and rs1456893 were significantly associated.
|
21830272 |
2011 |
|
Degenerative polyarthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Levels of proteasome subunit β type 3 (PSMB3), PSMB5, PSMB6, and proteasome assembly chaperone 1 were not decreased in OA chondrocytes.
|
29457374 |
2018 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In contrast to our previous EAE studies using PACAP global knockout mice which developed severe and prolonged EAE, we found that mice with conditional loss of PAC1 receptors in catecholaminergic cells developed a delayed time course of EAE with reduced helper T cell type 1 (Th1) and Th17 and enhanced Th2 cell polarization.
|
30058008 |
2019 |
|
Generalized Anxiety Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genotypes for PACAP/PAC1 were examined for effects on treatment response to venlafaxine XR in generalized anxiety disorder.
|
23972788 |
2013 |
|
Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time polymerase chain reaction (PCR) was used to examine the effects of haloperidol, olanzapine and amisulpride on the expression of genes coding PAC1/VPAC type receptors in the T98G glioblastoma cell line, as an example of an in vitro model of glial cells.
|
27900577 |
2017 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Synergistic activity of PAC-1/TMZ in rodent models and the demonstration of feasibility of the combined regime in canine patients suggest potential for PAC-1 in the treatment of glioblastoma.
|
29113289 |
2017 |